A subgroup of HER2+ BC cases, representing approximately 30% of HER2+ BC cases, co-expresses a heterogeneous collection of truncated HER2 CTFs, collectively called p95HER2, that lack the HER2 extracellular domain (ECD) and display distinct oncogenic potency [41,65]. This evidence concerns the gene ERBB2 and breast cancer.